Suchergebnisse - "Podzamczer, Daniel"

PubPharm (30)

1

Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide

enthalten in: The Journal of infectious diseases | 2023

von Scévola, S. | Niubó, J. | Domingo, P. | +10

2

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection : week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

enthalten in: The lancet. HIV | 2020

von Orkin, C. | DeJesus, E. | Sax, P. | +20

CommentIn: Lancet HIV. 2020 Jun;7(6):e374-e375. - PMID 32504568

3

Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40)

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2019

von Imaz, A. | Niubó, J. | Cottrell, M. | +6

4

Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

enthalten in: Journal of neurovirology | 2018

von Imaz, A. | Niubó, J. | Amara, A. | +7

5

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD) : 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Molina, J. | Squires, K. | Sax, P. | +113

CommentIn: Lancet HIV. 2018 May;5(5):e200-e201. - PMID 29592841

6

Short Communication : Maraviroc Once-Daily: Experience in Routine Clinical Practice

enthalten in: AIDS research and human retroviruses | 2017

von Saumoy, M. | Llibre, J. | Terrón, A. | +7

7

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen

enthalten in: The Journal of infectious diseases | 2016

von Imaz, A. | Martinez-Picado, J. | Niubó, J. | +9

CommentIn: J Infect Dis. 2016 Nov 15;214(10):1473-1474. - PMID 27578846

8

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients : 48 Week Results of the SIMRIKI Retrospective Study

enthalten in: PloS one | 2016

von Troya, J. | Ryan, P. | Ribera, E. | +19

ErratumIn: PLoS One. 2017 Feb 9;12 (2):e0172184. - PMID 28182783

9

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE) : a randomised, open-label, non-inferiority trial

enthalten in: The Lancet. Infectious diseases | 2015

von Arribas, J. | Girard, P. | Landman, R. | +118

CommentIn: Lancet Infect Dis. 2015 Jul;15(7):748-9. - PMID 26062879

10

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine : Final 48-Week Results (The Advanz-3 Trial)

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2015

von Miro, J. | Manzardo, C. | Ferrer, E. | +45